Tabula Rasa HealthCare to Present at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting

MOORESTOWN, N.J., March 13, 2017 -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) a disruptive innovation and technology leader in medication safety, offering a unique and proprietary Medication Risk Stratification and Medication Risk Mitigation Matrix® suite of medication decision support tools documented to improve health outcomes, has been selected to present four abstracts at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) to be held in Washington D. C. March 15-18, 2017.   The abstracts to be presented include:

* The Application of a Novel Medication Risk Stratification Tool to Identify High Risk Patients within a Large Population. This project identifies the potential health risks of a medication regimen and its importance for optimizing medication treatments.  By identifying patients at high risk for medication-related problems, those problems can be prevented, providing significant benefit for care providers and patients. This novel risk stratification tool can efficiently identify patients at high risk for medication-related issues based on their total medication regimens.

* Implementing a Standardized Medication Therapy Management Plus Approach within a Primary Care Setting.  The integration of pharmacogenomics (PGx) into medication therapy management (MTM) services could provide significant advancements in identifying and rectifying medication-related problems, especially Adverse Drug Events (ADEs). It is well-known that 25% of adults take at least one medication that commonly causes an ADE due to genetic variability. Enhancing MTM services by integrating PGx was well received by both prescribers and patients. Additionally, the PGx information increased the number of potential medication-related problems identified.  

* Medication-Specific Long-QT-JT Index and Patient-Specific Long-QT-JT Score for Assessing Risk of Torsade de Pointes: Validation in an Ambulatory Population. TRHC research focused on the drug-induced Long QT Syndrome and its relationship to the potentially fatal polymorphic ventricular tachycardia, Torsade de Pointes (TdP). Patients who take many medications may have individual risk factors that could predispose them to QT prolongation and TdP. The project created and validated drug-specific and patient-specific measures for risk of TdP.

* Visualization Technique for FAERS-Based Adverse Event Prediction. Monitoring Adverse Drug Events (ADEs) using the FDA Adverse Event Reporting System (FAERS) is essential for pharmacovigilance. More recently, this information source has become a resource for predicting ADEs as well. The objective of this study was to develop and implement a new technique to visualize FAERS data mining that provides clear, multi-dimensional insight into a patient’s drug regimen, and is intended to give clinicians an advantage when communicating with patients and their providers about potential ADEs.

“We are delighted and proud to have been selected to present at this prestigious conference of healthcare clinicians and scientists,” said Calvin H. Knowlton, PhD, TRHC Chairman and CEO. “These presentations exemplify the scientific quality of products developed by our clinical pharmacists and research teams.”

The 118^th annual meeting of the ASCPT is billed as “an outstanding scientific meeting that addresses cutting-edge issues in clinical pharmacology, translational and precision medicine, and other important topics in drug discovery, development, regulation and use.” Over 350 scientific posters, symposia, workshops, roundtables, and other offerings will take place during the 4-day meeting.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Since 2011, TRHC has focused on optimizing outcomes for healthcare organizations through its unique Medication Risk Mitigation software and Medication Decision Support and Adherence tools that personalize each participant's medication regimen.  For more information, please visit: www.TRHC.com.

Contact:                                                                                                                              

Media

Dianne Semingson
[email protected] 
T: 215-870-0829

Investors

Bob East or Asher Dewhurst
Westwicke Partners
443-213-0500
[email protected]